PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds

US11136395B2 · kind B2 · utility

Assignee

• Molecular Templates, Inc. · US

Inventors

• Eric Poma · New York, US
• Hilario Ramos · Austin, US
• Erin Willert · Round Rock, US
• Richard Shimkets · West Haven, US
• Crystal Jackson · Jefferson, US
• Thomas Vincent · Athens, US

Key dates

• Filing date: Sep 21, 2020
• Grant date: Oct 5, 2021
• Expiry date: Sep 21, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/16134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).